- Home
- SHFS vs MYNZ Comparison
SHFS vs MYNZ Comparison
Compare SHFS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHFS
- MYNZ
- Stock Information
- Founded
- SHFS 2015
- MYNZ 2021
- Country
- SHFS United States
- MYNZ Germany
- Employees
- SHFS N/A
- MYNZ N/A
- Industry
- SHFS Finance: Consumer Services
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- SHFS Finance
- MYNZ Health Care
- Exchange
- SHFS Nasdaq
- MYNZ Nasdaq
- Market Cap
- SHFS 6.2M
- MYNZ 5.5M
- IPO Year
- SHFS N/A
- MYNZ 2021
- Fundamental
- Price
- SHFS $3.27
- MYNZ $1.92
- Analyst Decision
- SHFS
- MYNZ Buy
- Analyst Count
- SHFS 0
- MYNZ 2
- Target Price
- SHFS N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- SHFS 36.3K
- MYNZ 154.3K
- Earning Date
- SHFS 08-13-2025
- MYNZ 07-22-2025
- Dividend Yield
- SHFS N/A
- MYNZ N/A
- EPS Growth
- SHFS N/A
- MYNZ N/A
- EPS
- SHFS N/A
- MYNZ N/A
- Revenue
- SHFS $13,956,453.00
- MYNZ $893,991.00
- Revenue This Year
- SHFS N/A
- MYNZ $26.06
- Revenue Next Year
- SHFS N/A
- MYNZ $4.97
- P/E Ratio
- SHFS N/A
- MYNZ N/A
- Revenue Growth
- SHFS N/A
- MYNZ N/A
- 52 Week Low
- SHFS $1.84
- MYNZ $1.34
- 52 Week High
- SHFS $14.86
- MYNZ $20.08
- Technical
- Relative Strength Index (RSI)
- SHFS 63.00
- MYNZ 57.87
- Support Level
- SHFS $2.14
- MYNZ $1.35
- Resistance Level
- SHFS $3.87
- MYNZ $2.15
- Average True Range (ATR)
- SHFS 0.31
- MYNZ 0.13
- MACD
- SHFS 0.11
- MYNZ 0.10
- Stochastic Oscillator
- SHFS 57.72
- MYNZ 71.67
About SHFS SHF Holdings Inc.
SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.